Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 2/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481443 | 0.84 | KMT2A (0.66) | KMT2AHIF1ATDP1PKMKDM4E | |
| Hydrochloric Acid SCHEMBL10388885 | 0.82 | KMT2A (0.63) | KMT2AHIF1ATDP1PKMKDM4E | |
| SCHEMBL113262 | 0.81 | KMT2A (0.61) | KMT2AHIF1ATDP1PKMKDM4E | |
| SCHEMBL11576418 | 0.81 | PLAU (0.64) | KMT2AHIF1ATDP1PKMKDM4E | |
| SCHEMBL5211055 | 0.78 | KMT2A (0.58) | KMT2AHIF1ATDP1PKMKDM4E | |
| SCHEMBL10981785 | 0.78 | KMT2A (0.58) | KMT2AHIF1ATDP1PKMKDM4E | |
| SCHEMBL5535275 | 0.78 | GAA (0.47) | KMT2ATDP1PKMKDM4ETSHR | |
| SCHEMBL2059557 | 0.77 | AGBL2 (0.46) | KMT2APKMKDM4EHTTMCL1 | |
| SCHEMBL5834958 | 0.77 | CYP2C19 (0.56) | KMT2AHIF1ATDP1PKMKDM4E | |
| SCHEMBL3727991 | 0.77 | TDP1 (0.70) | KMT2ATDP1PKMTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39707-E1 | Camptothecin derivatives | CATHOLIC HEALTHCARE WEST (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1353673-B1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2007-04-18 | — | — | EP | disclosed |
| CN-1553802-A | Camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-12-08 | — | — | CN | disclosed |
| US-20040034050-A1 | Homo-camptothecin derivatives | CATHOLIC HEALTHCARE WEST, DOING BUSINESS AS ST. MARY'S MEDICAL CENTER OF SAN FRANCISCO | 2004-02-19 | — | — | US | disclosed |
| WO-2003101406-A1 | HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1353673-A1 | CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002056885-A1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6350756-B1 | USEFUL FOR TREATING CANCER; (20S) ESTERS WITH AN OXYALKANOIC ACID; | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034050-A1 | Homo-camptothecin derivatives | CYP8B1, HCAR3, MTHFD2 | KMT2A 4155/4885HIF1A 1398/4885TDP1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.